XML 98 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($)
 12 Months Ended
Nov. 30, 2022
Nov. 17, 2022
Nov. 04, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Transaction costs related to sale of future revenues       $ 1,453,000
Total revenue       140,734,000 235,309,000 176,319,000
Drug Product Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       $ 11,086,000 962,000 8,906,000
NovaQuest [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Transaction costs related to sale of future revenues     $ 1,700,000      
Effective annual interest rate related to sale of future revenues       19.67%    
NovaQuest [Member] | Payment Cap Date on or before December 31, 2028 [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum payment cap amount     100,000,000.0      
NovaQuest [Member] | Payment Cap Date on or after January 1, 2029 [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum payment cap amount     112,500,000      
NovaQuest [Member] | Payment Cap Date after January 1, 2030 [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum payment cap amount     125,000,000.0      
Minimum [Member] | NovaQuest [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Prepayment amount of 2024 to 2030     80,000,000.0      
Minimum [Member] | NovaQuest [Member] | Before December 31, 2028 [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue interest payment     62,500,000      
Minimum [Member] | NovaQuest [Member] | No Later Than December 31, 2030 [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue interest payment     125,000,000.0      
Maximum [Member] | NovaQuest [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Prepayment amount of 2024 to 2030     125,000,000.0      
Product [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       $ 82,869,000 47,638,000 72,498,000
Product [Member] | NovaQuest [Member] | RIFA [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue interest payment     10,000,000.0      
License Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       22,590,000 116,434,000 14,323,000
Development Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       24,189,000 $ 70,275,000 $ 80,592,000
Astellas Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Future revenue granted     $ 50,000,000.0      
Percentage of revenue interest on global net sales     100.00%      
Received from sale of revenue   $ 49,800,000        
Gross proceeds received from sale of revenue   $ 50,000,000.0        
Astellas Agreement [Member] | Regulatory Milestone [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       25,000,000.0    
Astellas Agreement [Member] | Drug Product Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       11,100,000    
Non-cash interest expense related to drug product revenue       1,000,000.0    
Astellas Agreement [Member] | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue payment cap amount       125,000,000.0    
Astellas Agreement [Member] | Product [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage of revenue sold 22.50%          
Astellas Agreement [Member] | Milestone Payments [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage of revenue sold 10.00%          
Astellas Agreement [Member] | Milestone Payments [Member] | Before December 31, 2028 [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage of revenue sold 20.00%          
Astellas Agreement [Member] | License Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       22,600,000    
Astellas Agreement [Member] | Development Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenue       $ 2,400,000